Is this the year for precision psychology? With Amit Etkin

A quiet paradigm shift is underway in neuroscience as the industry begins to accept the idea of precision psychology – that is, using stronger data and better biomarkers to develop more effective treatments for specific groups of patients.

At the Sachs Neuroscience Forum just before the start of the JP Morgan Healthcare Conference in San Francisco, pharmaphorum’s Jonah Comstock spoke with Amit Etkin, CEO of Alto Neuroscience, about his company’s precision approach to psychology.

Etkin discusses what Alto has coming next year, including readouts for specialised drug candidates in schizophrenia, depression, and bipolar disorder. Some of these patients have limited or no options in the current standard of care.

He also discusses the importance of having a diversified pipeline, especially in CNS, and explains why he thinks an inflection point might be coming soon for neuro.

Check out the video below for the whole conversation, and stay tuned for more interviews from JPM week in San Francisco.